Holen Sie sich die Stockscreener-App
0.99
3.74%
-0.08
Handel nachbörslich:
1.00
0.01
+1.01%
Schlusskurs vom Vortag:
$1.07
Offen:
$1.1
24-Stunden-Volumen:
354.49K
Relative Volume:
0.37
Marktkapitalisierung:
$131.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.86M
KGV:
-0.0617
EPS:
-16.054
Netto-Cashflow:
$-17.68M
1W Leistung:
-13.45%
1M Leistung:
-59.29%
6M Leistung:
-43.09%
1J Leistung:
-85.53%
1-Tages-Spanne:
$0.9801
$1.24
1-Wochen-Bereich:
$1.01
$1.295
52-Wochen-Spanne:
$0.92
$8.57
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Firmenname
Indaptus Therapeutics Inc
Sektor
Branche
Telefon
(646) 427-2727
Adresse
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.99 | 142.57M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
Indaptus Therapeutics Stock Price Forecast. Should You Buy INDP? - StockInvest.us
Indaptus Therapeutics Inc (NASDAQ: INDP) Share Price, INDP Stock News, INDP Share Price & Updates - Kalkine
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1% - MarketBeat
Indaptus Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Indaptus Therapeutics Q2 EPS beats estimate as loss narrows - scanx.trade
Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot - TipRanks
Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary - TradingView
Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2 - Stock Titan
Indaptus Q2 Net Loss Narrows to $1.8 Million - Quiver Quantitative
Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise - Stock Titan
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indaptus Therapeutics (INDP) to Announce Earnings on Monday - MarketBeat
Qinglai Lu Net Worth (2026) - GuruFocus
Indaptus Therapeutics Inc (INDP) Stock News Today - TradingKey
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 88.8% in July - MarketBeat
Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.610|Chg%:-0.160 - TradingKey
Indaptus Therapeutics Inc (INDP) Balance Sheet - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.100|Chg%:+0.060 - TradingKey
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Indaptus Therapeutics Inc (INDP) Cash Flow - TradingKey
Indaptus Therapeutics Market Sentiment - Benzinga España
Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.060|Chg%:-0.550 - TradingKey
Indaptus Therapeutics, Inc. Revenue Breakdown – NASDAQ:INDP - TradingView
Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey
TradingKey - TradingKey
Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Indaptus Therapeutics (INDP) Q3 2025 earnings summary - Quartr
Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting - Nonstop Local News
Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan - Stock Titan
INDP Q4 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Navigates Clinical DevelopmentQuarterly Financial Update - po-news-eg.net
Insider Traders Lose US$34k As Indaptus Therapeutics Drops - simplywall.st
INDP Q4 2025 Earnings: Wider-than-Expected Loss as Stock Declines Nearly 6%Revenue Estimate Trend - dars.gov.et
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q4 2025 Earnings: EPS Misses Expectations Amid Zero Revenue; Stock Declines 1.96%Cost Structure Review - po-news-eg.net
Indaptus Therapeutics (INDP) News Flow - Moomoo
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Surprise Score - dars.gov.et
Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com - Investing.com Australia
Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares - Stock Titan
Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake - Stock Titan
Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance - Stock Titan
Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused - Stock Titan
Revenue per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
Indaptus Therapeutics Announces Private Placement of Common Stock - The Globe and Mail
INDAPTUS THERAPEUTICSTO ISSUE 20 MLN SHARES AT $0.6 PER SHARESEC FILING - Moomoo
Indaptus TherapeuticsTo Issue 20 Million Shares At $0.6 Per ShareSEC Filing - TradingView
Finanzdaten der Indaptus Therapeutics Inc-Aktie (INDP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.20%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):